GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

brolucizumab   Click here for help

GtoPdb Ligand ID: 8713

Synonyms: Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
Approved drug
brolucizumab is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Brolucizumab is a single-chain variable fragment (scFv) anti-VEGF antibody targeting vascular endothelial growth factor A (VEGFA). This immunobinder was derived from a humanised anti-VEGFA rabbit monoclonal [2].
Peptide sequence and secondary structural information are available from brolucizumab's IMGT/mAb-DB record.
Peptide sequence alignment analysis of patented peptide sequences using the heavy chain variable region of brolucizumab identifies a 100% match with SEQ ID NO: 164 in patent US8349322 B2 [1].

Following regulatory approval brolucizumab took its place as a wet age-related macular degeneration therapy alongside aflibercept (Eylea®) and ranibizumab (Lucentis®), which were previously the main drugs used for this indication. However, with patent protection for both of these older dugs due to expire in the next 2-5 years [4], brolucizumab will likely face competition from aflibercept and ranibizumab biosimilars.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. US FDA (2019)  |  EU EMA (2020)
International Nonproprietary Names Click here for help
INN number INN
10053 brolucizumab
Synonyms Click here for help
Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 536
Reactome Drug Reactome logo R-ALL-9679482
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 252827371
Search PubMed clinical trials brolucizumab
Search PubMed titles brolucizumab
Search PubMed titles/abstracts brolucizumab